We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
(-36%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-34.19%
Top 10 Holdings %
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$32.3M |
| 2 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$32.3M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$30.9M |
| 4 |
Eli Lilly
LLY
|
+$30M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$143M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$52.9M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$39.4M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$34.5M |
| 5 |
Travere Therapeutics
TVTX
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.5% |
| 2 | Financials | 0.29% |
| 3 | Consumer Discretionary | 0.04% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $289M | 9.05% |
26,895,532
-660,313
| -2% | -$5.44M |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $192M | 6.03% |
2,866,863
+486,153
| +20% | +$30.9M |
|
|
CERE
3
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $134M | 4.21% |
5,086,727
| – | – |
|
4
Iovance Biotherapeutics
IOVA
$2.09B
| $131M | 4.09% |
11,826,299
-374,962
| -3% | -$4.91M |
|
|
LIAN
5
DELISTED
LianBio American Depositary Shares
LIAN
| $122M | 3.83% |
56,560,211
+240,251
| +0.4% | +$816K |
|
6
Crinetics Pharmaceuticals
CRNX
$8.88B
| $99.2M | 3.11% |
5,321,032
+157,515
| +3% | +$3.14M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $96.3M | 3.02% |
3,015,054
-877,439
| -23% | -$25.7M |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $95.2M | 2.98% |
3,867,446
-660,547
| -15% | -$24.2M |
|
|
9
Amylyx Pharmaceuticals
AMLX
$2.2B
| $68.2M | 2.14% |
3,540,408
+2,066,301
| +140% | +$24.5M |
|
10
Xenon Pharmaceuticals
XENE
$6.19B
| $64.6M | 2.02% |
2,122,535
-288,912
| -12% | -$8.74M |
|
11
MeiraGTx Holdings
MGTX
$1.08B
| $52.7M | 1.65% |
6,963,277
+15,000
| +0.2% | +$146K |
|
|
LYRA
12
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $51.7M | 1.62% |
182,935
+118,484
| +184% | +$32.3M |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $51.1M | 1.6% |
5,534,169
-2,602,461
| -32% | -$21.3M |
|
|
RXDX
14
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $47.5M | 1.49% |
1,682,242
-758,340
| -31% | -$22M |
|
|
ALBO
15
DELISTED
Albireo Pharma Inc
ALBO
| $46.9M | 1.47% |
2,360,139
| – | – |
|
|
CINC
16
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $43.7M | 1.37% |
2,319,117
| – | – |
|
|
VBIV
17
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $42.3M | 1.33% |
1,744,500
| – | – |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $39.6M | 1.24% |
+224,000
| New | +$32.3M |
|
19
Veru
VERU
$35.5M
| $39.5M | 1.24% |
350,000
-86,200
| -20% | -$10M |
|
20
Aldeyra Therapeutics
ALDX
$95.9M
| $39.5M | 1.24% |
9,903,879
| – | – |
|
21
Neurocrine Biosciences
NBIX
$18.3B
| $38.8M | 1.21% |
397,888
+2,249
| +0.6% | +$208K |
|
|
RAPT
22
DELISTED
RAPT Therapeutics
RAPT
| $34.9M | 1.09% |
239,224
-110,771
| -32% | -$14.8M |
|
23
Relay Therapeutics
RLAY
$4.09B
| $32.5M | 1.02% |
1,943,097
| – | – |
|
|
24
Eli Lilly
LLY
$1.09T
| $32.4M | 1.02% |
+100,000
| New | +$30M |
|
25
Cogent Biosciences
COGT
$6.85B
| $27.9M | 0.87% |
3,088,972
-99,778
| -3% | -$681K |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.
- Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
- Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
- Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
- Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
- Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
- Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
- Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.
Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.